Systemic sclerosis among hospitalized patients in Poland: a study based on a national hospital registry.

**Abstract**

**Introduction**

Systemic sclerosis (SSc) is a rare, autoimmune disease with possible life-threatening internal organ involvement. Because of its rarity and heterogeneous clinical presentation, studies on this disease may be difficult to carry out. OBJECTIVES We sought to describe patients at first hospitalization for SSc in Poland from 2013 to 2019. The study measured SSc incidence trend, comorbidities, factors related to this disease among hospitalized patients in Poland.

**Material and methods**

We conducted a retrospective, population-based study using hospital discharge records compiled by the National Institute of Public Health.

**Results**

The study group covered 4,633 patients hospitalized with SSc diagnosis for the first time in 2013-2019. The mean and median age were 53.9 (95% CI: 53.4 – 54.3, SD: 16.6) and 57 years (IQR: 44 - 66). In the study group, female patients accounted for 81.3% of all patients, and they were significantly older than male patients (54.6 vs 50.4 years; P<0.001). The crude incidence was estimated at 1.72 per 100 000 person-years (95% CI 1.67-1.77). The SSc incidence rate was significantly higher in urban than rural areas of Poland (1.83 vs 1.46 per 100,000; P<0.001). In patients with progressive systemic sclerosis in comparison to other forms of SSc we observed a significantly rare presence of selected groups of diseases.

**Conclusions**

Presented data on SSc in Poland may also be helpful in comparative analyses in the European context. Territorial factors may have a significant impact on the occurrence of SSc in Poland.

**Explanation letter**

Dears,

Responses to Reviewers in the attachment.
Flow chart in the attachment (Figure 1.docx)

Sincerely,

Corresponding author
Systemic sclerosis among hospitalized patients in Poland: a study based on a national hospital registry.

INTRODUCTION Systemic sclerosis (SSc) is a rare, immune-mediated rheumatic disease characterized by tissue fibrosis of the skin and internal organs, and vasculopathy. In 2013, a joint committee of the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) presented classification criteria for SSc [1].

SSc is a rare disease. The reported prevalence of SSc was 7.2 – 33.9 and 13.5 – 44.3 per 100,000 individuals in Europe and North America, respectively. Annual incidence estimates were 0.6 – 2.3 and 1.4 – 5.6 per 100,000 individuals in Europe and North America, respectively [2]. In a systematic review and meta-analysis, the incidence rate of SSc ranged from 0.77 per 100,000 person-years in the Netherlands to 5.6 per 100,000 person-years in the USA. Reported prevalence ranged from 3.8 per 100,000 in Taiwan to 50 per 100,000 in the USA [3]. In another systematic review and meta-analysis the overall pooled prevalence of SSc was 17.6 per 100,000 and the overall pooled incidence rate of SSc was 1.4 per 100,000 person-years [4].

The pathogenesis of SSc is still unclear, although it may result from interactions between environmental factors and epigenetic features leading to the onset and progression of SSc in group of genetically susceptible patients. The association between SSc and occupational exposure may be variable according to gender [5]. A correlation is reported to exist between occupational exposure to crystalline silica/solvents and more severe forms of SSc characterized by: diffuse cutaneous involvement, interstitial lung disease, general microangiopathy, and association with cancer [6]. Occupational
exposure to silica or solvents is highly prevalent in male patients with systemic sclerosis [7]. The effect of low median household income is demonstrated as a factor heightening the risk of death in SSc patients [8]. Other risk factors reported are age between 45 and 64 years, the female sex, positive family history and exposure to silica [9]. Men with SSc were found to be exposed to a higher risk of developing cancer than women [10]. In other studies, age at disease onset, the male sex, diffuse cutaneous SSc, cardiac and renal involvement, interstitial lung disease, pulmonary hypertension, and malignancy were found to be associated with a worse prognosis [11].

Patients with SSc have higher mortality rates than the general population [12], [13]. The worldwide age-standardized mortality rate in systemic sclerosis (deaths per millions) was reported to be 1.46 in 2014 [14]. In high-income societies, SSc has a poor prognosis, as in about 55% of affected patients the disease is a direct cause of death [15]. In the other study, respiratory failure from interstitial lung disease (ILD) was reported to be the main cause of death in most SSc-ILD patients [16]. In a study from Denmark, one fifth of all deaths were attributable to cardiovascular causes, one fourth to pulmonary diseases, and 15% of deaths were caused by cancer [17]. In a study from the United Kingdom survival at 1, 5, and 10 years was found to be 94.2, 80.0, and 65.7%, respectively [18]. In a multicenter, French cohort study the overall survival rates at 1, 3, 5, and 10 years from diagnosis were 98.0%, 92.5%, 85.9%, and 71.7% respectively. In a study conducted in Australia, an overall standardized mortality ratio of 3.4 and a 10-year survival of 84% was reported in newly diagnosed patients [19].

Various comorbidities were associated with substantial and significant differences in the risk of in-hospital mortality [20]. Moreover, SSc is associated with an increased risk of cancer, particularly lung, liver, hematologic, and bladder cancers [10],
Another meta-analysis revealed a higher mortality rate in SSc patients with associated digital ulcers [22].

SSc is considered to be an economic burden on health care systems [23, 24, 25]. There are studies on the SSc epidemiology or comorbidities in SSc in Poland [26, 27, 28, 29, 30, 31, 32, 33]. However, research on this rare disease based on national hospital morbidity registers may be justified and necessary.

**OBJECTIVES**  
We sought to describe patients at the time of first hospitalization for SSc in Poland between 2013 and 2019. The study measured the SSc incidence trend, comorbidities, and factors related to this disease among hospitalized patients in Poland.

**MATERIAL AND METHODS**  
The study is a retrospective study based on data from hospital discharge records that included an SSc diagnosis. Data were obtained from the National Institute of Public Health NIH - National Research Institute in Poland and they covered 22,908 all first-time and subsequent hospitalization cases reported between 2013 and 2019. For the extended identification of first-time hospitalizations, data on hospitalizations from previous years were also used [26]. The study group consisted of 4,633 first-time hospitalization cases of SSc patients in the studied period of time as presented in the flow chart in Figure 1. We analyzed the records of patients hospitalized for SSc diagnosed as the primary or secondary disease. All hospitals in Poland, except for psychiatric facilities, are required under the law to submit electronically data from hospitalization to the Institute with use of the official form MZ / Szp-11. The data are anonymous and they contain information on ICD10-code diagnoses, hospital admission and discharge data, the sex of the patient, their date of
birth and place of residence. The local bioethics committee was informed about the study. Based on the information obtained from the committee, in the case of retrospective and non-invasive research studies, the ethics committee does not issue an opinion. SSc often requires advanced differential diagnostic procedures and treatment during hospitalization. Therefore, hospitalized cases may provide a good basis for estimating incidence. We assumed that SSc diagnoses were made in hospitals on the basis of the most current and widely used diagnostic criteria.

STATISTICAL ANALYSIS  To perform the statistical analyses, Statistica [34] and WINPEPI [35] were used. The following statistical measures were computed: means, medians, and ranges for continuous variables, counts and percentages for categorical variables. The incidence was calculated per 100 000 person-years and the prevalence was calculated per 100 000 for the period 2013-2019. To assess trends, we used linear regression, time series analysis. The statistical analysis was performed using the t-Student test with respect to an assumption of normal distribution in sufficiently large samples in public health research [36]. When normality assumptions were not met, non-parametric tests (chi square test, Mann-Whitney U-test) were applied. For comparison of nominal variables the chi square tests were used. A two-sided P value of less than 0.05 was considered to be statistically significant. Data on the overall population of Poland were taken from the Statistics Poland [37], [38]. In the analyzes of comorbidities, selected groups of diseases according to the ICD-10 classification were compared.
RESULTS

In the study group females predominated (81.3% vs. 18.7% males) with female to male ratio at 4.34 to 1, and in subgroups of patients with progressive SSc (81.8%) and subgroup of all other forms of SSc (81%). The mean and median age was 53.9 (95%CI: 53.4 – 54.3, SD: 16.6) and 57 years (IQR: 44 – 66, min-max: 1-106). The age distribution in the study group is presented in Figure 2. Female patients were significantly older than males in the study group (54.6 vs 50.4 years, P < 0.001). We observed no significant increase or decrease trends in SSc incidence in the study group in the analyzed period of time. The crude incidence was estimated at 1.72 per 100 000 person-years (95% CI 1.67-1.77). The crude SSc incidence rate was significantly higher in urban than rural areas of Poland (1.83 vs 1.46 per 100,000; P<0.001). The prevalence was estimated at 12 per 100,000 during the study period. The most common groups of co-morbidities among patients in the study group were cardiovascular diseases (23.6%), diseases of the musculoskeletal system and diseases of connective tissue other than SSc (17.7 %), endocrine, nutritional and metabolic diseases (13.6%), diseases of the respiratory system (11.1%), digestive system diseases (7.1%), with other groups of diseases being below 5% separately. Patients with neoplasms accounted for 2% of SSc patients. In the study group most often observed were neoplasms of uncertain behavior of middle ear and respiratory and intrathoracic organs (ICD-10 code: D38) – 10 cases, malignant neoplasm of bronchus and lung (ICD-10 code: C34) – 9 cases, Malignant neoplasm of breast (ICD-10 code: C50) - 8 cases, lymphoid leukemia (ICD-10 code: C91) - 8 cases. In the study group among the cardiovascular disease most of them were arterial hypertension (14.7%), Raynaud's syndrome (3.5%), heart failure (2.5%), chronic ischemic heart disease (1.8%). Pulmonary hypertension (ICD-10 code: I27.0,
I27.2) was observed in 0.6% of the study group. Other interstitial pulmonary diseases (ICD-10 code: “J84”) were observed in 6.5% of the study group.

Among groups of diseases of the musculoskeletal system and diseases of connective tissue other than SSc most of them were polyosteoarthritis (ICD10 code: M15) – 196 cases, spondylosis (ICD10 code: M47) – 177 cases, Other systemic involvement of connective tissue (ICD10 code: M35) – 117 cases.

In the study group endocrine, nutritional and metabolic diseases were more often observed in females than males (14.6% vs 8.1%, P<0.001). Diseases of the respiratory system were more often observed in males than females (13.7% vs 10.5%, P<0.01). Diseases of the digestive system were more often observed in males than females (8.9% vs 6.6%, P<0.03). Neoplasms were more often observed in males than females (3.1% vs 1.8%, P<0.05)

In the group of all hospitalizations, 243 patients died during hospitalization (5.2% of all patients). In the study group, 56 patients died during hospitalization (1.2% of all patients). Among all 243 fatal hospitalizations the mean and median age was 65.3 (95%CI: 63.7 – 67, SD: 13.3) and 67 years (IQR: 57 – 74). Male patients were significantly more often observed in fatal hospitalizations than non-fatal hospitalizations (30% vs 18%; P<0.001). The most common groups of co-morbidities among 243 patients with fatal hospitalizations were cardiovascular diseases (65.8%), diseases of the respiratory system (50.2%), and diseases of the genitourinary system (23.9%). Neoplasms were observed in 7.4% of SSc patients with fatal hospitalizations. The reported leading underlying causes of in hospital death was SSc (57%), diseases of the circulatory system (15%), diseases of the respiratory system (7%), other cases were separately below 5%. Among death cases as a underlying or other cause of death heart
failure I50 was reported in 98 cases, other interstitial pulmonary diseases “j84” in 21 cases, pulmonary hypertension (I27.0, I27.2) in 6 cases.

In the present work, patients were divided into two groups of patients in progressive SSc and patients with other forms of SSc. Distribution of these two groups of SSc patients among first-time hospitalizations by year is presented in Figure 3. Patients with progressive SSc accounted for 29% of all SSc patients in the study group. The data concerning the comparison between groups of patients with progressive SSc and other forms of SSc are presented in Table 1.

**DISCUSSION**

SSc is a rare disease and the use of national hospital morbidity registers may contribute to a better understanding of factors related to the disease. The reported incidence was comparable to that reported in many European countries [2]. Additionally, the recent reported SSc incidence was lower than the data collected in an earlier Polish study based on national hospital morbidity registers reporting the crude average annual SSc incidence at the level 1.9 per 100,000 [26]. In our study no significant changes in the trend of SSc occurrence were found. However, in terms of overall SSc incidence, a minor increase was observed in a nationwide cohort study from Denmark over the study period from 1995 to 2015 [17]. It may suggest that the trends in SSC incidence may be related to territorial factors.

Territorial factors are still considered to play an important role in disease development. In recent study based on data from SSc the southeast region of Romania, the majority of SSc patients came from urban areas [39]. Marked differences in SSc prevalence according to age, sex, and region were also reported in other study from
Quebec based on physician billing and hospitalization databases (covering approximately 7.5 million individuals) [40]. In our study, no sufficient information on territorial factors in the nationwide morbidity registry was obtained. However, we noticed significant differences in SSc incidence between urban and rural areas in Poland. This may lead to the assumption that there may be territorial or environmental factors influencing the risk of SSc in these areas in Poland. However, further research is required to confirm this relationship.

Females were the majority of patients in our study. Marked female preponderance was also reported in studies analyzed in the recent systematic review [9]. The proportion of women in the study group was lower than in the previous study [26]. Similarly, in a nationwide cohort study from Denmark 76% of all patients with a SSc diagnosis were women and a drop in the proportion of women was reported [17]. In the study group females dominated in all patients and in subgroups of patients with progressive SSc and subgroup of all other forms of SSc. The female domination was also reported in selected groups of SSc patients from the EUSTAR database [41].

In our study male patients were significantly more often observed in fatal hospitalizations than non-fatal hospitalizations. It is possible that the disease presentation in more severe in male patients. Moreover, in a study from Poland it was also suggested that SSc males patients with other selected factor may have severe and rapidly progressive disease [42]. Another study reported that men tend to display a more severe expression of the disease including internal organ-based complications and higher mortality than women [43].

In the case of progressive systemic sclerosis, the process of skin and internal organs involvement may be greater, the course of the disease may be rapid, especially in
the initial stage of the disease. It was also reported that clinical phenotypes at disease onset may predict morbidity and mortality in SSc [44]. In the present study, 29% diagnoses of progressive SSc were observed among all forms of SSc as presented in Figure 3. The percentage of progressive SSc was lower than that presented in previous study from Poland [26]. In the present work, patients were divided into two groups of patients in progressive SSc and patients with other forms of SSc. In the first group there were significantly lower incidences of selected diseases in comparison to the second group as presented in Table 1. This observation may suggest that the type of comorbidities may be a predictor of a specific form of SSc. Additionally, it is worthy to be highlighted that this statistically significant difference in the occurrence of certain comorbidities was possible to identify when using the national hospital morbidity registry. Age among the study groups presented in Table 1 was comparable. In the large multicenter prospective EUSTAR cohort based on observational data of SSc patients aged >= 18 years, mean age in groups of limited cutaneous SSc cases and diffuse cutaneous systemic sclerosis cases was comparable and reported to be 57 and 58 years, respectively [41].

In our study, SSc patients with neoplasms accounted for 2% of all studied patients. In comparison, it was estimated that for every 100,000 people in the Polish population in 2017, 429 people were diagnosed with cancer, and approximately 2,623 lived with a cancer diagnosis over the last 15 years [45]. In the group of patients with fatal hospitalizations in our study the presence of neoplasms was observed in 7.4% of patients. In a study conducted in Australia it was found that cardiorespiratory manifestations were the leading cause of SSc-related deaths, whereas malignancy was reported to be the leading cause of deaths not related to SSc [19]. There is a possibility
that a similar relationship may be observed among SSc patients in Poland. Further studies *are necessary to perform* a better analysis of the cause of death in SSc hospitalized patients in Poland.

In our study we observed relatively low prevalence of pulmonary hypertension, and it may be related to organization of health care in Poland. The relatively low prevalence of pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD) was reported in a study based on data from the Polish Registry of Pulmonary Hypertension. However, among patients with CTD-PAH, the most frequent were diseases of the scleroderma spectrum. Authors of this study suggested that CTD-PAH patients were lost, either by never getting a diagnosis or by not reaching the designated PAH centre [46].

The reported mortality risks in the study group seem to be low. In the study from the USA among a large cohort from 2011-2019 of SSc patients hospitalized due to SSc and non-SSc related causes, overall inpatient mortality was reported to be 9.3% [47].

Our study also had several limitations. The hospital discharge database analyzed did not include other variables that might be related to SSc. Also, the database included discharge records from inpatient hospitalizations only, which means it excluded SSc patients who were diagnosed or treated as outpatients only. This inaccuracy may result in the underestimation of the incidence rate. For 93 patients (2% of all patients in the study group) no reliable data on the place of residence code was available. The coding practices for SSc-related hospitalizations have not been assessed. This inaccuracy may have resulted in an imprecise estimation of SSc cases. However, the long observation period and the relatively large size of data obtained from the national register of hospital morbidity speak to the advantage of this study.
CONCLUSIONS  Presented data on SSc in Poland may also be helpful in comparative analyses in European context. Territorial factors may have a significant impact on the occurrence of SSc in Poland.

CONFLICT OF INTEREST  Authors declare no conflict of interest in relation to this article. There were no external sources of funding for this study.

FIGURE LEGENDS
Figure 1: Flow chart. The study group identification.
Figure 2: Age distribution of SSc cases in the study group by gender 2013-2019
Figure 3: Distribution of SSc forms among first-time hospitalizations by year, 2013-2019

TABLE LEGENDS
Table 1. Comparison between groups of patients with progressive SSc and other forms of SSc
REFERENCES

1. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2013; 72: 1747–55.

2. Bergamasco A, Hartmann N, Wallace L, Verpillat P. Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease. Clin Epidemiol 2019; 11: 257–273.

3. Zhong L, Pope M, Shen Y, Hernandez JJ, Wu L. Prevalence and incidence of systemic sclerosis: A systematic review and meta-analysis. Int J Rheum Dis 2019; 22: 2096–2107.

4. Bairkdar M, Rossides M, Westerlind H, Hesselstrand R, Arkema EV, Holmqvist M. Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis. Rheumatology (Oxford) 2021; 0: 1-13.

5. Marie I, Gehanno J-F, Bubenheim M, Duval-Modeste A-B, Joly P, Dominique S, et al. Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature. Autoimmun Rev 2014; 13: 151–156.

6. Marie I, Menard J-F, Duval-Modeste A-B, Joly P, Dominique S, Bravard P, et al. Association of occupational exposure with features of systemic sclerosis. J Am Acad Dermatol 2015; 72: 456–464.

7. De Decker E, Vanthuyne M, Blockmans D, Houssiau F, Lenaerts J, Westhovens R, et al. High prevalence of occupational exposure to solvents or silica in male systemic sclerosis patients: a Belgian cohort analysis. Clin Rheumatol 2018; 37: 1977–1982.

8. Calderon LM, Pope JE. Scleroderma epidemiology update. Curr Opin Rheumatol 2021; 33: 122–127.

9. Abbot S, Bossingham D, Proudman S, de Costa C, Ho-Huynh A. Risk factors for the development of systemic sclerosis: a systematic review of the literature. Rheumatol Adv Pract 2018; 2: rky041.

10. Onishi A, Sugiyama D, Kumagai S, Morinobu A. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum 2013; 65: 1913–1921.

11. Pokeerbux MR, Giovannelli J, Dauchet L, Mouthon L, Agard C, Lega JC, et al. Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature. Arthritis Res Ther 2019; 21: 86.
12. Lee YH. Overall and sex- and disease subtype-specific mortality in patients with systemic sclerosis: An updated meta-analysis. Z Rheumatol 2019; 78: 195–201.

13. Rubio-Rivas M, Royo C, Simeón CP, Corbella X, Fonollosa V. Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum 2014; 44: 208–219.

14. Scherlinger M, Mertz P, Sagez F, Meyer A, Felten R, Chatelus E, et al. Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014. Autoimmun Rev 2020; 19: 102531.

15. Tyndall AJ, Bannert B, Vonk M, Airò P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010; 69: 1809–1815.

16. Volkmann ER, Fischer A. Update on Morbidity and Mortality in Systemic Sclerosis-Related Interstitial Lung Disease. J Scleroderma Relat Disord 2021; 6: 11–20.

17. Butt SA, Jeppesen JL, Fuchs C, Mogensen M, Engelhart M, Torp-Pedersen C, et al. Trends in incidence, mortality, and causes of death associated with systemic sclerosis in Denmark between 1995 and 2015: a nationwide cohort study. BMC Rheumatol 2018; 2: 36.

18. Royle JG, Lanyon PC, Grainge MJ, Abhishek A, Pearce FA. The incidence, prevalence, and survival of systemic sclerosis in the UK Clinical Practice Research Datalink. Clin Rheumatol 2018; 37: 2103-2111.

19. Morrisroe K, Stevens W, Proudman S, Nikpour M. A systematic review of the epidemiology, disease characteristics and management of systemic sclerosis in Australian adults. Int J Rheum Dis 2017; 20: 1728–1750.

20. Amoda O, Ravat V, Datta S, Saroha B, Patel RS. Trends in Demographics, Hospitalization Outcomes, Comorbidities, and Mortality Risk among Systemic Sclerosis Patients. Cureus 2018; 10: e2628.

21. Peng H, Wu X, Wen Y, Li C, Lin J, Li J, et al. Association between systemic sclerosis and risk of lung cancer: results from a pool of cohort studies and Mendelian randomization analysis. Autoimmun Rev 2020; 19: 102633.

22. Meunier P, Dequidt L, Barnette C, Lazaro E, Duffau P, Richez C, et al. Increased risk of mortality in systemic sclerosis-associated digital ulcers: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2019; 33: 405–409.

23. Fischer A, Zimovetz E, Ling C, Esser D, Schoof N. Humanistic and cost burden of systemic sclerosis: A review of the literature. Autoimmun Rev 2017; 16: 1147–1154.
24. Morrisroe K, Stevens W, Sahhar J, Ngian G-S, Rabusa C, Ferdowsi N, et al. Quantifying the direct public health care cost of systemic sclerosis: A comprehensive data linkage study. Medicine (Baltimore). 2017; 96: e8503.

25. Fischer A, Kong AM, Swigris JJ, Cole AL, Raimundo K. All-cause Healthcare Costs and Mortality in Patients with Systemic Sclerosis with Lung Involvement. J Rheumatol 2018; 45: 235–241.

26. Kanecki K, Goryński P, Tarka P, Wierzbą W, Tyszko P. Incidence and prevalence of Systemic Sclerosis (SSc) in Poland - differences between rural and urban regions. Ann Agric Environ Med 2017; 24: 240–244.

27. [Assessment of ECG and holter parameters among patients with systemic sclerosis]. Przegl Lek. 2016; 73: 364–367. [Article in Polish.]

28. Ciurzyński M, Bienias P, Irzyk K, Kostrubiec M, Szewczyk A, Demkow U, et al. Clinical research Heart diastolic dysfunction in patients with systemic sclerosis. Arch Med Sci 2014; 10: 445–454.

29. Wielosz E, Borys O, Błaszczak P, Majdan M. [Heart involvement in systemic sclerosis: analysis of four cases]. Ann Acad Med Stetin. 2012; 58: 33–39; discussion 39. [Article in Polish]

30. Dworniak K, Duchnowicz P, Koter-Michalak M, Dziankowska-Bartkowiak B, Gerlick Z, Waszczykowska E, et al. [Increased level of lipid peroxidation products and disturbances in oxidation-reduction balance in erythrocytes from patients suffering from systemic sclerosis, who are chronically treated with vitamin E]. Pol Merkur Lekarski 2013; 35: 85–88. [Article in Polish]

31. Dryglewskal M, Majdan M, Koszarny A, Grytal A, Grzywnowicz M. [Evaluation of usefulness of Polycheck method in the detection autoantibodies in patients with systemic lupus erythematosus, Sjögren’s syndrome and systemic sclerosis]. Wiad Lek 2015; 68: 252–258. [Article in Polish]

32. Mekal D, Deptala A. [Evaluation of nutritional status in patients with systemic sclerosis]. Pol Merkur Lekarski 2021; 49: 40–43. [Article in Polish]

33. Chrabaszcz M, Małyszko J, Sikora M, Alda-Malicka R, Stochmal A, Matuszkiewicz-Rowinska J, et al. Renal Involvement in Systemic Sclerosis: An Update. Kidney Blood Press Res 2020; 45: 532–548.

34. TIBCO Software Inc. Statistica (data analysis software system), version 13. http://statistica.io. 2017.

35. Abramson JH WINPEPI updated: computer programs for epidemiologists, and their teaching potential. Epidemiol Persp 2011; 8: 1.

36. Lumley T, Diehr P, Emerson S, Chen L. The Importance of the Normality Assumption in Large Public Health Data Sets. Annu Rev Public Health 2002; 23: 151–169.
37. Statistics Poland. https://stat.gov.pl (accessed 30 May 2021).

38. Statistics Poland. https://stat.gov.pl/obszary-tematyczne/ludnosc/ludnosc/ludnosc-stan-i-struktura-ludnosci-oraz-ruch-naturalny-w-przekroju-terytorialnym-stan-w-dniu-31-12-2019,6,27.html. (accessed 11 October 2020).

39. Bobeica C, Niculet E, Craescu M, Onisor C, Bujoreanu F, Draganescu ML, et al. Epidemiological profile of systemic sclerosis in the southeast region of Romania. Exp Ther Med 2021; 21: 77.

40. Bernatsky S, Joseph L, Pineau CA, Belisle P, Hudson M, Clarke AE. Scleroderma prevalence: demographic variations in a population-based sample. Arthritis Rheum 2009; 61: 400–404.

41. Frantz C, Huscher D, Avouac J, Hachulla E, Balbir-Gurman A, Riemekasten G, et al. Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database. Autoimmun Rev 2020; 19: 102452.

42. Widuchowska M, Glowacka M, Kopeć-Mędrek M, Kotulska A, Trzaska-Sobczak M, Kucharz E. Rapidly progressive systemic sclerosis with a fatal outcome in male patients. Reumatologia 2010; 48: 45–48.

43. Hughes M, Pauling JD, Armstrong-James L, Denton CP, Galdas P, Flurey C. Gender-related differences in systemic sclerosis. Autoimmun Rev 2020; 19: 102494.

44. Panopoulos S, Bournia V-K, Konstantonis G, Fragiadaki K, Sfikakis PP, Tektonidou MG. Predictors of morbidity and mortality in early systemic sclerosis: Long-term follow-up data from a single-centre inception cohort. Autoimmun Rev 2018; 17: 816–820.

45. Didkowska J, Wojciechowska U, Czderny K, Olasek P, Ciuba A. Cancer in Poland 2017. Polish National Cancer Registry. Department of Epidemiology and Cancer Prevention. Warsaw; 2019.

46. Kopeć G, Kurzyna M, Mroczek E, Chrzanowski Ł, Mularek-Kubzda T, Skoczylas I, et al. Characterization of Patients with Pulmonary Arterial Hypertension: Data from the Polish Registry of Pulmonary Hypertension (BNP-PL). J Clin Med 2020; 9: E173.

47. Sankar S, Habib M, Jaafar S, Nagaraja V, Roofeh D, Young A, et al. Hospitalisations related to systemic sclerosis and the impact of interstitial lung disease. Analysis of patients hospitalised at the University of Michigan, USA. Clin Exp Rheumatol 2021; 39 Suppl 131(4): 43–51.
Table 1. Comparison between groups of patients with progressive SSc and other forms of SSc.

|                          | Patients with progressive SSc (coded as M34.0), N=1344 | Patients with other forms of SSc, N=3289 | P       |
|--------------------------|--------------------------------------------------------|-----------------------------------------|---------|
| Female vs Male           | 81.8% vs 18.2%                                         | 81% vs 19%                              | NS      |
| AGE - mean, standard deviation | 55, 14.9                                              | 53.4, 17.2                              | <0.01   |
| Percentage of patients living in urban areas | 63.9%                                                   | 66.2%                                  | NS      |
| Endocrine, nutritional and metabolic diseases | 10.6% (143)                                            | 14.8% (487)                            | <0.001  |
| Cardiovascular diseases  | 19.3% (260)                                            | 25.3% (833)                            | <0.001  |
| Diseases of the respiratory system | 11.4% (153)                                            | 10.9% (360)                             | NS      |
| Diseases of the digestive system | 6.1% (82)                                              | 7.4% (245)                             | NS      |
| Diseases of the musculoskeletal system and connective tissue other than SSc | 15.6% (210)                                            | 18.5% (608)                            | <0.05   |

P – statistical significance.

NS – statistically not significant
Figure 1: Flow chart. The study group identification.

Hospital discharge records obtained from the National Institute of Public Health NIH: 22908 hospitalization records identified in 2013-2019

Preliminary identification of first-time hospitalization based on data from 2013-2019: 6078 records

Extended identification of first-time hospitalizations. A number of 1445 records excluded from 6078 hospitalization records.

Final study group of first-time hospitalization: 4633 records.

Figure 1: Flow chart. The study group identification.
Figure 2: Age distribution of SSc cases in the study group by gender 2013-2019
Figure 3: Distribution of SSc forms among first-time hospitalizations by year, 2013-2019